-
1.发明公开INDOLEAMINE 2,3-DIOXYGENASE PATHWAYS IN THE GENERATION OF REGULATORY T CELLS 审中-公开吲哚胺2,3-双加氧酶-WAY在生产调节性T细胞
公开(公告)号：EP1981534A2
公开(公告)日：2008-10-22
申请号：EP07717763.2
申请日：2007-01-05
申请人： Medical College of Georgia Research Institute, Inc , Chen, Wei , Blazar, Bruce R. , Munn, David , Mellor, Andrew , Regents of the University of Minnesota
发明人： CHEN, Wei , BLAZAR, Bruce, R. , MUNN, David , MELLOR, Andrew
IPC分类号： A61K39/00 , A61K31/405
CPC分类号： C07D471/04 , A61K31/405 , C07D209/12 , C07D209/14 , C07D209/20 , C07D209/36 , C07D209/40 , C07D209/94 , C07D213/74 , C07D215/26 , C07D233/56 , C07D307/77 , C07D307/92 , C07D311/92 , C07D333/58 , C07D403/06 , C07D417/04 , C07D491/04 , C07D513/04
摘要： The present invention provides methods for the control of the generation of regulatory T cells (Tregs) and uses thereof.
-
2.发明公开THE INDUCTION OF INDOLEAMINE 2,3-DIOXYGENASE IN DENDRITIC CELLS BY TLR LIGANDS AND USES THEREOF 审中-公开确保-吲哚胺2,3-加氧酶树突状细胞TLR配体及其用途
公开(公告)号：EP1937303A2
公开(公告)日：2008-07-02
申请号：EP06836384.5
申请日：2006-10-20
发明人： MELLOR, Andrew , MUNN, David
IPC分类号： A61K39/00 , A61K31/404
CPC分类号： A61K39/001 , A61K31/404 , A61K2039/55516 , A61K2039/55561
摘要： The induction of indoleamine 2,3-dioxygenase (IDO) in an IDO-competent subset of dendritic cells by TLR ligands, including TLR9 ligands, and various uses thereof are presented.
-
3.发明公开ANTIGEN-PRESENTING CELL POPULATIONS AND THEIR USE AS REAGENTS FOR ENHANCING OR REDUCING IMMUNE TOLERANCE 审中-公开抗原细胞群及其作为试剂增益或减少免疫耐受
公开(公告)号：EP1501918A1
公开(公告)日：2005-02-02
申请号：EP02807233.8
申请日：2002-04-12
发明人： MELLOR, Andrew , MUNN, David
CPC分类号： C12N5/064 , A61K2035/122 , C12N2501/22 , C12N2501/23 , C12N2501/70
摘要： The present invention is based on the discovery antigen-presenting cells (APCs) may be generated to have predetermined levels of expression of the intracellular enzyme, indoleamine 2,3-dioxygenase (IDO). Because expression of high levels of IDO is correlated with a reduced ability to stimulate T cell responses and an enhanced ability to induce immunologic tolerance, APCs having high levels of IDO may be used to increase tolerance in the immune system, as for example in transplant therapy or treatment of autoimmune disorders. For example, APCs having high levels of IDO, and expressing or loaded with at least one antigen from a donor tissue may be used to increase tolerance of the recipient to the donor's tissue. Alternatively, APCs having reduced levels of IDO expression and expressing or loaded with at least one antigen from a cancer or infectious pathogen may be used as vaccines to promote T cell responses and increase immunity.
-
-
搜索结果
3 条记录 (耗时 0.018 秒)
